Insmed nabs new patent for ARIKAYCE in U.S.

|About: Insmed Incorporated (INSM)|By:, SA News Editor

The USPTO has issued Insmed Incorporated (NASDAQ:INSM), patent No. 10,251,900 for certain uses of ARIKAYCE (amikacin liposome inhalation suspension).

The claims of the patent relate in part to methods for treating Mycobacterium avium complex (MAC) lung disease via administration of ARIKAYCE to patients previously unresponsive to MAC therapy.

This is the 10th patent issued by the USPTO for ARIKAYCE in MAC lung disease and second with an expiry date of May 15, 2035.

Subscribe for full text news in your inbox